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Abstract. The receptor tyrosine kinase Tie1 is expressed
primarily in vascular endothelial cells. The receptor has also
been detected in epithelial tumours in breast, thyroid and
gastric cancers and in tumour cell lines where it appears as a
45 kDa truncated receptor fragment. In this study, we show
that in addition to truncated Tie1, breast and colon tumour
cell lines express a full-length Tie1 holoreceptor. In contrast
to the situation in endothelial cells, Tie1 truncation is not
activated by phorbol esters and generation of truncated Tie1
does not occur via a metalloprotease-inhibitor sensitive
mechanism. Examination of the phosphorylation status of
Tie1 revealed both the holoreceptor and truncated receptor to
be constitutively activated in MCF-7 cells. These data
indicate that Tie1 expressed in epithelial tumour cell lines is
present in holoreceptor and truncated forms, and in MCF-7
cells both forms are constitutively phosphorylated and
competent to signal. Our findings suggest therefore that anti-
angiogenic strategies targeting the angiopoietin/Tie system in
tumour microvasculature could also have additional direct
effects on the tumour epithelial cells within those tumours in
which there is also extravascular expression of the Tie1
receptor tyrosine kinase. 
Introduction
The angiopoietins are a family of secreted glycoprotein
ligands whose expression is markedly altered in a wide range
of cancers, including breast, colorectal and gastric tumours
(1). There are four members of the angiopoietin family,
angiopoietin-1 (Ang1) through angiopoietin-4, with Ang3 and
Ang4 being mouse and human orthologues respectively
(2-4). The angiopoietins are all ligands for Tie2, a receptor
tyrosine kinase predominantly expressed by vascular endo-
thelial cells (5). As with angiopoietins, expression of Tie2
has been shown to be increased in cancer, indeed Tie2
expression correlates with poor survival and high metastatic
risk in breast cancer, including node-negative breast cancers
(6,7). Of the angiopoietins, the best characterized are Ang1
and Ang2. Ang1 is an activator of Tie2 whereas Ang2 can
antagonize Ang1 activation (3). In quiescent vasculature
Ang1 is produced by perivascular cells and acts to promote
blood vessel stability (2,8). Expression of Ang2 is more
dynamically regulated than that of Ang1 and up-regulation
of Ang2 occurs under conditions of vessel remodelling
where it can suppress the effects of Ang1 and thus permit
vessel destabilization prior to angiogenesis or regression (3).
Consistent with the notion that Ang2 promotes angiogenesis
by destabilization of microvessels, the ratio of Ang2/Ang1
is elevated in most of the cancers in which expression has
been examined (1).
Tie2 together with Tie1 constitute the Tie family of
receptor tyrosine kinases and as with Tie2, Tie1 is expressed
principally by vascular endothelial cells (9). Tie1 and Tie2
have a similar overall structure, with an extracellular domain
composed of three immunoglobulin-like repeats, three
epidermal growth factor homology domains followed by a
further immunoglobulin motif and three fibronectin III
domains (10-12). The intracellular portions of each receptor
include a tyrosine kinase domain with kinase insert. Overall
amino acid identity between the receptors is approximately
30% in the extracellular domain and 75% in the intracellular
domain (10,11). In contrast to Tie2, relatively little is known
about the Tie1. This is partly because a ligand for this receptor
has not been available. However, studies with transgenic
mice indicate that Tie1 is important for promoting endothelial
survival (13,14). This is supported by experiments in which a
chimaeric form of Tie1 expressed in mouse fibroblasts was
shown to inhibit cell death induced by UV irradiation (15).
Tie1 undergoes regulated proteolytic cleavage in which
the extracellular domain of the receptor is released from the
cell as a result of metalloprotease action (16-18). Cleavage is
activated by a number of factors including phorbol esters and
vascular endothelial growth factor (VEGF) and generates a
cell-associated receptor fragment of approximately 45 kDa
consisting of Tie1 transmembrane and intracellular domains
(16-18).
It has been found that Ang1 can activate Tie1 in
endothelial cells and when the receptor is transfected into
non-endothelial cells (19). As with Tie2, Ang2 antagonizes
Ang1 activation of Tie1 in endothelial cells (19). Tie1 and
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Tie2 physically interact in endothelial cells (20) and
stimulation of Tie1 by Ang1 is enhanced in the presence of
Tie2, although the ligand is still able to stimulate Tie1 even
in the absence of Tie2 (19).
Tie1 expression is increased in a number of tumours,
and the receptor has been suggested as a prognostic marker
for gastric cancer where its expression correlates inversely
with patient survival (21). Importantly, immunocytochemical
analysis has shown that in addition to the vascular com-
partment, Tie1 is expressed in epithelial tumour cells in breast
(22-24), gastric (21) and thyroid (25) cancers. Consistent
with these findings, several breast and colon tumour cell
lines have also been shown to express Tie1, where it appears
to exist in the truncated 45 kDa form (24). In this study, we
determined whether this tyrosine kinase is competent to
signal in tumour cells in which it is expressed.
Materials and methods
Materials. Antibodies recognizing the carboxy-terminus of
Tie1, and immunogen peptide were obtained from Santa
Cruz Biotechnology, antibodies recognizing Tie1 extra-
cellular domain were from R&D Systems. Recombinant Ang1
and Ang2 were from R&D Systems (Abingdon, Oxon, UK).
All other materials were as previously described (20,26).
Cell culture. Human umbilical endothelial cells (HUVEC)
were obtained from Promocell and cultured as described
by the supplier. Cancer cell lines were originally obtained
from European Cell Culture Collection. CACO-2 cells were
maintained in MEM with 10% FCS, MCF-7 and MDA-MB-
231 cells were maintained in DMEM with 10% FCS, MDA-
MB-436 and HCT-15 cells were maintained in RPMI-1640
containing 10 and 20% FCS respectively. SW480 cells were
maintained in Optimem I containing 10% FCS.
Immunoprecipitation and immunoblotting. Cells were
maintained as described above. In experiments involving
treatment with phorbol esters, metalloprotease inhibitor or
angiopoietin cells were incubated in serum-free medium for
approximately 1 h before treatment. Whole cell lysates
were prepared by washing cells in phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM
KH2PO4; PBS) followed by addition of 2X Laemmli sample
buffer containing 100 mM dithiothreitol. For immunopre-
cipitation cells were lysed with ice cold lysis buffer (50 mM
Tris, pH 7.4; 50 mM NaCl; 1 mM sodium fluoride, 1 mM
EGTA, 1 mM sodium orthovanadate, 1% Triton X-100,
complete protease inhibitor cocktail), cleared of particulate
matter by centrifugation at 13,000 x g for 10 min, pre-
adsorbed with protein-G before immunoprecipitation with
2 μg primary antibody and protein-G for 3 h. Recovered
immunoprecipitates were washed 3 times with lysis buffer
and proteins eluted by heating at 105˚C in Laemmli sample
buffer containing 100 mM dithiothreitol. Proteins were
resolved by sodium dodecylsulphate polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes and probed with appropriate antibodies as
indicated in results. Immunoreactive proteins were visualized
with peroxidase-conjugated secondary antibodies and chemi-
luminescent detection (27). Where required, membranes
were stripped using Reblot, as described by the manufacturer
(Chemicon International Inc., Temecula, CA, USA) before
blocking and re-probing.
Results
Previous studies have demonstrated expression of the
endothelial receptor tyrosine kinase Tie1 in a number of
tumours in both vascular and tumour cell compartments
(21-25). Consistent with this the receptor has been found
to be expressed in several epithelial tumour cell lines
including the breast cancer line MCF-7 (24). Significantly,
Tie1 was detected as the 45 kDa receptor fragment in these
cells (24). Although the receptor has been found in cancer
cells its activation state is not known. We were interested
therefore to determine the activation state of Tie. In initial
experiments we sought to confirm expression of the truncated
receptor in MCF-7 cells. As shown in Fig. 1A, immuno-
blotting MCF-7 cell lysates with an antibody recognizing
the carboxy-terminus of Tie1 revealed a doublet of 45 kDa
Tie1, as described previously by others (24). In addition
to truncated Tie1, we also observed a protein doublet of
approximately 145 kDa in MCF-7 cells, similar to that seen
in endothelial cells (Fig. 1A). This protein corresponds to
an upper band of fully glycosylated surface expressed
receptor (Fig. 1A, arrowhead) and partially glycosylated
Tie1 as described previously (16). To further test whether
full-length Tie1 is present in MCF-7 cells we used antibodies
recognizing the fully glycosylated extracellular domain of
Tie1 and a non-specific antibody to immunoprecipitate from
MCF-7 cell lysates (Fig. 1B). Antibodies recognizing the
extracellular domain of Tie1, but not the control antibody,
immunoprecipitated a single 145 kDa protein corresponding
to fully-glycosylated Tie1 holoreceptor.
Together these data show that in addition to the
previously reported 45 kDa Tie1 truncation product, full-
length Tie1 is also expressed in MCF-7 cells. We therefore,
tested whether full-length receptor is present in other
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Figure 1. MCF-7 cells express full-length and truncated Tie1. Human
umbilical vein endothelial cells or MCF-7 cells were harvested and lysed.
(A) Proteins in whole cell lysates were resolved by SDS-PAGE and Tie1
detected by immunoblotting. The fully glycosylated holoreceptor is indicated
with an arrowhead. (B) Cell lysates were immunoprecipitated with an
irrelevant antibody (ns) or antibody recognizing Tie1 extracellular domain.
Immunoprecipitated proteins were resolved by SDS-PAGE and Tie1 detected
by immunoblotting. Molecular masses are indicated in kDa.
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epithelial tumour lines. A number of tumour cell lines were
probed for the presence of Tie1 by immunoblotting. As
shown in Fig. 2, a number of these cell lines, including the
colon tumour lines HCT-15 and SW480, as well as the breast
cancer lines MCF-7 and MDA-MB-436 expressed clearly
detectable 145 kDa Tie1, whereas levels in CACO-2 and
MDA-MB-231 were barely detectable. Re-probing blots
with anti-Tie1 but in the presence of a peptide corresponding
to the Tie1 immunogen prevented the antibody reacting
with the 145 kDa protein confirming it as Tie1.
In endothelial cells Tie1 holoreceptor undergoes costi-
tutive proteolytic cleavage to generate the 45 kDa truncation
product comprising of transmembrane and intracellular
domains (16,17). This process is stimulated by phorbol
esters as well as the physiological activators VEGF, TNFα
and changes in shear stress (16,18,28,29). Constitutive and
activated cleavage of Tie1 is mediated by metalloprotease
activity (17). It was of interest, therefore, to determine
whether similar mechanisms operate on Tie1 in cancer cells.
To do this, we challenged MCF-7 cells with PMA in the
absence and presence of the metalloprotease inhibitor
TAPI-2 and analysed Tie1 by immunoblotting with an anti-
body recognizing the receptor intracellular domain (Fig. 3).
Consistent with previous findings, PMA activated cleavage
of Tie1 in endothelial cells causing loss of the surface
expressed full-length 145 kDa protein and formation of a
45 kDa doublet fragment (Fig. 3A). In the presence of
TAPI-2 PMA was without effect on full-length receptor and
generation of 45 kDa Tie1 was largely ablated (Fig. 3A). In
contrast, treatment of MCF-7 with the same concentration
of PMA did not affect levels of full-length or 45 kDa Tie1.
Similarly, TAPI-2 was without detectable effect on truncated
or full-length Tie1 in MCF-7 cells (Fig. 3B). Together, these
data show that Tie1 expressed in MCF-7 is regulated
differently than Tie1 expressed in the normal endothelial
cell background.
To examine the signalling potential of Tie1 in cancer
cells the receptor was immunoprecipitated from MCF-7
cells and receptor activation assessed by examining tyrosine
phosphorylation status. As we had found some full-length
receptor in MCF-7 cells it was possible that Tie1 holore-
ceptor could respond to angiopoietin ligands. Therefore, to
investigate this we analyzed tyrosine phosphorylation state
of full-length and truncated Tie1 immunoprecipitated from
MCF-7 cells cultured under basal conditions and following
treatment with Ang1 or Ang2. Tie1 holoreceptor was immuno-
precipitated from MCF-7 cells with an antibody recognizing
the receptor ectodomain and phosphorylation status assessed
by anti-phosphotyrosine immunoblotting (Fig. 4A). Tie1
(145 kDa) holoreceptor was found to be phosphorylated in
MCF-7 cells (Fig. 4A). Surprisingly, Ang2 did not inhibit the
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Figure 2. Full-length Tie1 is expressed by colon and breast epithelial tumour
cell lines. Whole cell lysates were prepared from the cell lines indicated and
proteins were resolved by SDS-PAGE and Tie1 detected by immunoblotting
(upper panel). The lower panel shows the result of re-probing the blot with
anti-Tie1 in the presence of 1 μg/ml immunogen peptide. Molecular masses
are indicated in kDa.
Figure 3. Effects of PMA and metalloprotease inhibitor on Tie1 cleavage.
Human umbilical vein endothelial cells (A) or MCF-7 cells (B) were treated
with control vehicle (Cont.), 10 ng/ml phorbol myristate acetate (PMA)
for 30 min or PMA in the presence of 100 μM TAPI-2 (PMA + TAPI-2) for
30 min before harvesting and preparation of whole cell lysates. Proteins in
whole cell lysates were resolved by SDS-PAGE and Tie1 detected by
immunoblotting. Molecular masses are indicated in kDa.
Figure 4. Tie1 is tyrosine phosphorylated in MCF-7 cells. Serum-deprived
MCF-7 cells were treated with control vehicle (Cont.), 200 ng/ml Ang1 or
200 ng/ml Ang2 for 30 min as indicated. Cell lysates were prepared and
Tie1 immunoprecipitated with an antibody recognizing the receptor extra-
cellular domain (A) or intracellular carboxy-terminus (B). Immuno-
precipitated proteins were resolved by SDS-PAGE and phosphorylation
status (PY) detected by immunoblotting with anti-phosphotyrosine
antibodies. Blots were re-probed with anti-Tie1 as indicated. Molecular
masses are indicated in kDa.
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constitutive phosphorylation of Tie1 in these cells; instead
the ligand caused a small increase in phosphorylation of
the receptor. Ang1 also caused a small additional activation
of phosphorylation of full-length Tie1 (Fig. 4A). Phospho-
rylation status of the truncated 45 kDa Tie1 was also
assessed by anti-phosphotyrosine immunoblotting of the
receptor immunoprecipitated with an antibody recognizing
the Tie1 intracellular domain (Fig. 4B). Under basal
conditions truncated Tie1 was tyrosine phosphorylated
and there was little detectable effect of Ang1 or Ang2 on
phosphorylation status of the endodomain fragment.
Discussion
In this study, we show that a number of epithelial cancer
cells express the endothelial receptor tyrosine kinase Tie1 as
a holoreceptor. We further demonstrate that in contrast to the
situation in endothelial cells, generation of truncated Tie1
does not occur via a metalloprotease-inhibitor sensitive
mechanism and that the constitutive production of truncated
Tie1 cannot be activated by PMA in the MCF-7 breast cancer
cell line. Examination of the phosphorylation status of
Tie1 revealed both holoreceptor and truncated receptor to
be constitutively activated in MCF-7 cells.
Tie1 has been shown to be expressed in several tumour
types in both vascular and tumour cell compartments (21-25).
Furthermore, the receptor has been shown to be expressed in
several tumour cell lines, including MCF-7, where it was
found primarily in truncated 45 kDa forms. The present data
demonstrate also expression of the full-length receptor.
Certainly it would be expected that cells expressing truncated
Tie1 would have some full-length receptor as this is the
source of the truncated receptor. It is clear from studies in
endothelial cells that Tie1 is sensitive to proteolytic cleavage
(16). Tumour cell lines as well as tumours in vivo are known
to express a number of proteases, including matrix metallo-
proteases, stromolysin and plasminogen activator, and the
tumour microenvironment is known to be pro-proteolytic
(30-32). It is likely, therefore that undetectable or low levels
of full-length Tie1 but clearly evident truncated Tie1 indicates
that normally in these cells most of the receptor is
proteolytically cleaved and that holoreceptor represents a
small fraction of the total receptor under these conditions.
The nature of the protease responsible for cleaving
Tie1 in MCF-7 cells is not known. In contrast to endothelial
cells, the metalloprotease inhibitor TAPI-2 failed to inhibit
truncation of Tie1. It is also interesting that, again in contrast
to the receptor in its normal endothelial cell background,
PMA was without effect on Tie1 truncation in MCF-7 cells.
This may indicate that cleavage of the receptor is already
maximal in the cancer cells so additional activators would
be ineffective. Also, in endothelial cells activation of Tie1
cleavage by PMA is mediated by metalloprotease activity
(17). As we find metalloprotease inhibitor to be without
effect on MCF-7 Tie1 cleavage it suggests that the normally
regulated metalloprotease pathway of Tie1 cleavage is
dominated by an alternative non-regulated, non-metallo-
protease pathway in these cancer cells.
An important finding of the present study is that in
MCF-7 cells the full-length receptor and truncation product
is phosphorylated under basal conditions. Constitutive
activation of other receptor tyrosine kinases is commonly
observed in tumour cells in culture as well as in situ, and
can occur by mutation and overexpression mechanisms
(33). Even though Tie1 holoreceptor was constitutively
phosphorylated we found that Ang2, which usually acts to
inhibit Ang1 signalling through the Tie receptors in endo-
thelial cells (3,19), did not to suppress Tie1 phosphorylation
in MCF-7 cells but, if anything, caused a small activation.
The receptor was also still able to respond to Ang1 with a
small increase in activation. There are a number of studies of
angiopoietin expression during tumourigenesis and in most
cases angiopoietin expression is substantially increased,
particularly the relative expression of Ang2 compared to
Ang1. Our data would suggest these ligands could act on
Tie1 expressed in the tumour cells to maintain or even
activate the receptor.
In summary, our data show that Tie1 is expressed in a
number of breast and colon cancer cell lines as both full-
length and truncated receptor forms. In MCF-7 cells the
receptor and its truncation product is phosphorylated
under basal conditions. These findings indicate that Tie1
expressed within tumour epithelium is constitutively active
and competent to signal. The angiopoietins and their better
characterized receptor Tie2 have recently emerged as
potentially attractive targets for anti-angiogenic therapy
of tumours (34,35). The finding that Tie1 is present and
constitutively active, as judged by receptor phosphorylation
status, would suggest that therapeutics aimed at sequestering
angiopoietins may also have effects directly on the tumour
cell to limit the ability of the angiopoietins to act on Tie1 in
tumour cells. Furthermore, the tyrosine kinase domains of
Tie1 and Tie2 are highly homologous. Thus, anti-angiogenic
tyrosine kinase inhibitors aimed at suppressing endothelial
Tie2 would be likely also to affect Tie1 and thus may have
direct, probably desirable, additional direct inhibitory effects
on any full-length as well as truncated Tie1 expressed in the
tumour cells.
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